Figure 2From: Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease Mean (±standard error) change from baseline in FEV 1 over 24 hours by treatment; represents the results for the peak change in FEV 1 (the primary efficacy endpoint) as well as the change in FEV 1 from test-day baseline over time. Back to article page